Alginic sodium diester sustained-release capsule and application thereof in treating cerebral ischemia-reperfusion injury

A technology of sodium alginate and sustained-release pellets, which is applied in the treatment of cerebral ischemia-reperfusion injury. In the field of sodium alginate sustained-release capsules, it can solve the problem of inability to maintain stable and effective blood drug concentration and biological half-life Short, short action time and other issues, to achieve the effect of inhibiting the formation of thrombus, lowering blood lipids, inhibiting the occurrence and development

Inactive Publication Date: 2020-04-07
WUXI CHILDRENS HOSPITAL
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Currently on the market, bis-fatty sodium alginate tablet has fast oral absorption and a short biological half-life. Generally, it needs to be taken 3 times a day, which cannot maintain a stable and effective blood drug concentration, and the action time is short, which is prone to dizziness, increased blood pressure, Asthma and other adverse reactions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Alginic sodium diester sustained-release capsule and application thereof in treating cerebral ischemia-reperfusion injury
  • Alginic sodium diester sustained-release capsule and application thereof in treating cerebral ischemia-reperfusion injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045] 1. Investigation of enteric-coated materials

[0046] The enteric-coated material of the present invention is selected from HPMCAS, HPMCP, Eudragit S100, Eudragit RL100, and Eudragit RS100 as the enteric-coated material, and the influence of different enteric-coated materials on the extrusion process and the release of the drug in vitro is investigated. Among them, HPMCAS has the smallest torque during extrusion, and the color of the extrudate is the most similar to that of the API, and there is no polymerization phenomenon in the pH1.0 medium, indicating that the enteric-coated material has a good wrapping effect on the main drug, preventing ring-opening polymerization of the main drug. Therefore, HPMCAS is preferred as the enteric carrier material.

[0047] 2. Proportion inspection

[0048] The ratio of the main drug to the enteric material usually affects the feasibility of extrusion, the dissolution and stability of the drug. In this experiment, the mass ratio of t...

Embodiment 2

[0052] Investigate the dosage of main and auxiliary materials, and use the orthogonal experimental design method to screen the dosage of main and auxiliary materials:

[0053] The main drug is sodium alginate: 10-20 parts;

[0054] Enteric-coated material: 10-20 parts, one or more selected from HPMCAS, HPMCP, Eudragit S100, Eudragit RL100, and Eudragit RS100; HPMCAS is preferred as the enteric-coated material.

[0055] Diluent: 20-30 parts, one or more selected from starch, powdered sugar, lactose, β-cyclodextrin, and microcrystalline cellulose; microcrystalline cellulose is not absorbed in the body, and its compressibility It has good fluidity and has a certain capillary action. When it meets water, it can make water quickly enter the core of the ball and destroy the combination between the particles, which is helpful for the rapid disintegration of the drug. Therefore microcrystalline cellulose is preferably used as diluent.

[0056] Binder: 2 to 10 parts, one or more sele...

Embodiment 3

[0066] Embodiment 3 The preparation of sustained-release capsules of the present invention, based on 500 calculations, the specification is 30mg,

[0067] The prescription for medicated pill cores is as follows:

[0068] Sodium alginate: 15g,

[0069] HPMCAS: 15g,

[0070] Microcrystalline cellulose: 25g,

[0071] Polyvinylpyrrolidone: 8g, selected from polyvinylpyrrolidone,

[0072] Di-tert-butylhydroxytoluene: 2g, selected from di-tert-butylhydroxytoluene,

[0073] Magnesium stearate: 2g,

[0074] Enteric coating liquid prescription is as follows:

[0075] HPMCP: 10g,

[0076] castor oil 2g,

[0077] Sodium Lauryl Sulfate: 2g,

[0078] Water: Appropriate amount,

[0079] Coating weight gain 10%;

[0080] The preparation method of sodium alginate sustained release capsule comprises the following steps:

[0081] Step 1, preparation of skeleton-type drug-containing pellets: use sodium alginate as the raw material, enteric-coated materials and pharmaceutically accepta...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an alginic sodium diester sustained-release capsule and application thereof in treating cerebral ischemia-reperfusion injury. According to the existing listed alginic sodium diester tablets, the oral absorption of the tablet is quick and the biological half-life period is short; the alginic sodium diester tablet needs to be taken 3 times each day generally and the stable and effective blood concentration can not be kept; the acting time is short; and adverse reactions such as dizziness, blood pressure rise and asthma are caused easily. The alginic sodium diester sustained-release capsule is convenient for dose division and is convenient to take, and the compliance of patients is improved. The alginic sodium diester sustained-release capsule can be uniformly distributed in gastrointestinal tracts after being absorbed by human bodies; burst release is not caused easily; the stable and effective blood concentration can be kept; the stability is high and the bioavailability is improved.

Description

technical field [0001] The invention belongs to the technical field of pharmaceutical preparations, and in particular relates to a sodium alginate slow-release capsule and its application in treating cerebral ischemia-reperfusion injury. Background technique [0002] Cerebral apoplexy is one of the major diseases that endanger human health, and ischemic cerebral apoplexy accounts for 80%-85% of cerebral apoplexy. At present, thrombolysis is the main treatment for ischemic stroke, but it is easy to cause oxidative stress and lead to cerebral ischemia-reperfusion injury when the blood supply is restored. [0003] Sodium alginate is a seaweed extract, which is a new heparin-like drug, but it has no heparin-like toxic and side effects, and has strong dispersion and emulsification properties, so that the surface of red blood cells rich in negative charges can enhance mutual repulsion, so it can Resists the adhesion between red blood cells or between red blood cells and casts, th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/52A61K9/50A61K47/38A61K31/737A61P9/10
CPCA61K9/5042A61K9/5089A61K31/737A61P9/10
Inventor 凌菁菁王燕洪远陈艳华周丹丽
Owner WUXI CHILDRENS HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap